Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • studythosestocks studythosestocks Mar 5, 2013 11:29 PM Flag

    Preview of Steve Rosenman's article coming out in the AM.

    I haven't read it yet but just found it. Enjoy.

    seek^ngalpha.c*m/author/steve-rosenman/instab*og

    replace with i,o,l

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Haha, just the same old cr*p, nothing new and a laughable pumper "interview" with Rhagu the #$%$:)

      Stock will continue to sink like Titanic while Steve Rosenscam and Rhagtard are making love in their cabin!

      LMFAO:)

      Sentiment: Strong Sell

    • Very thorough and logical. Steve effortlessly separates himself from the tabloid journalists like Adam and Alex. They're not even in the same class for those who are looking for solid DD.

    • Just read Steve's article. Very well done and could not agree more. I seldom say a stock is a "no brainer" but there are exceptions.

    • SR is serious, factual and professional. I wonder how soon we hear more BS from AF?

      Sentiment: Strong Buy

    • Fantastic insight from Steve there. I wasn't aware of the background of the guy behind Aegis, so great to hear that he's very experienced in this arena.

      I like what he says here:

      "Dr. RS: It's not a question of if, its a question of when. What I can say is that if AMRN gets approval for Vascepa in mixed dyslipidemia based on the ANCHOR Phase 3 data, pharmaceutical companies will have to make bids for AMRN to get their hands on the asset. These are companies with thousands of sales reps on the sideline and billions of dollars in patent cliffs eroding as we speak. They cannot afford to wait. Even worse, they cannot allow one of their competitors to take control of this drug. We still expect that a bidding war could break out over AMRN.

      For Marine, $15-$20 is a reasonable target. If we were several years out and still required a clinical study for Anchor, I'd agree not to bake it in now. But, with a sNDA filed and approval likely in 2013, we are only months away from a potential game-changing blockbuster. Approval is likely under special protocol assessment from FDA, outcome trials approved and enrolled and a highly successful phase-3 trial."

      Sentiment: Strong Buy

    • Just read it -- it is a magnificent read. I know SR got some dates wrong before with expecting NCE and such, but this is an excellent article. If I were AMRN, I would hire this guy as a spokesperson or at least give him stock options.

      Sentiment: Strong Buy

      • 2 Replies to barnes.nathaniel
      • It was a good read wasn't it.

        Complete and factual.

        You can disagree with Steve if you want but at least he has laid out his argument clearly. I particularly enjoyed the interview with the sell side analyst from Aegis Capital.

        We will know more in May but I anticipate FDA accepting our sNDA. I tend to be a little more pesimistic that it will be closer to EOY before we hear from them. Are sNDA's generally shorter than 10 month review?

        My price target is a little lower than Steve's but I agree that everyone is overlooking Anchor. There may be time to get in the game down the road but I'm not taking that chance. I added a little last week and may add some more if NCE is denied.

        Short sqeeze is inevitable and will probably sell portions of my shares into major catalyst events in the next 10 months.

 
AMRN
2.26+0.06(+2.73%)4:00 PMEDT